Immune Tolerance Network

免疫耐受网络

• 批准号: 10116129
• 负责人: GERALD T NEPOM
• 金额: $ 2955.03万
• 依托单位: BENAROYA RESEARCH INST AT VIRGINIA MASON
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-02-01 至 2028-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10116129
• 关键词: Address; Adopted; Affect; Allergic Disease; Area; Autoimmune Diseases; Autoimmunity; California; Clinical Research; Clinical Sciences; Clinical Trials; Clinical assessments; Communities; Development; Discipline; Disease; Fostering; Freedom; Funding; Future; Genetic; Goals; Health; Health Care Costs; Hypersensitivity; Immune Tolerance; Immunologics; Immunology; Industry; Institution; Intervention; Knowledge; Laboratories; Lead; Leadership; Life; Medical; Mission; National Institute of Allergy and Infectious Disease; Organ failure; Phase; Population; Process; Quality of life; Research Design; Research Institute; Research Personnel; Resource Sharing; Resources; Role; Sampling; San Francisco; Savings; Structure; Therapeutic; Therapeutic immunosuppression; Transplantation; United States; Universities; base; burden of illness; clinical application; clinical research site; data integration; data management; data sharing; design; drug withdrawal; empowered; experience; flexibility; improved; innovation; next generation; novel; operation; preclinical study; programs; response; success; tool

Project summary / ABSTRACT The mission of the ITN is to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics based upon testable mechanistic hypotheses. The ITN is structured in order to interrogate different diseases across the immunologic spectrum, with integration of innovative clinical studies and cutting edge immunology laboratory analysis. The ITN approach—clinical assessment of novel tolerance therapeutics, while we simultaneously evaluate the cellular, genetic, and immunologic mechanisms of disease and how they are altered in response to therapy—creates a framework for advancing cross-disease and cross-discipline knowledge, all designed to accelerate therapeutic options for major diseases. In this renewal application, we describe the scientific and operational framework that will enable the ITN to successfully enhance the development of tolerance therapies in transplantation, autoimmunity, and allergy. We outline a process to evolve our current strategies into the next generation of planned trials, as well as how we plan to operate a nimble, future-focused organization, poised to lead and adopt innovations that are currently unknown. We propose a collaborative structure involving hundreds of investigators, advisors, and clinical sites working in tandem with a core group of ITN staff, operating a program that is both scientifically and financially efficient. Several new innovations recently adopted by the ITN will encourage widespread involvement from academic investigators, including expanded resource sharing and data sharing operations. With lead institutional commitment from the Benaroya Research Institute and the University of California San Francisco, and participation of more than 20 other major institutions represented in leadership and major advisory roles, the ITN strives to continue to successfully pioneer high impact clinical trials and mechanistic studies in areas of unmet medical need.

项目摘要/摘要